TARS - Tarsus Pharmaceuticals Inc Stock Price, Fair Value and News

25.02USD-3.22 (-11.40%)Delayed

Market Summary

USD25.02-3.22

Delayed

-11.40%

TARS Alerts

1 major insider sales recently.

TARS Stock Price

View Fullscreen

TARS RSI Chart

TARS Valuation

Market Cap

945.3M

Price/Earnings (Trailing)

-6.38

Price/Sales (Trailing)

20.98

EV/EBITDA

-6.63

Price/Free Cashflow

-7.02

TARS Price/Sales (Trailing)

TARS Profitability

EBT Margin

-301.58%

Return on Equity

-53.85%

Return on Assets

-42.43%

Free Cashflow Yield

-14.24%

TARS Fundamentals

TARS Revenue

Revenue (TTM)

45.1M

Rev. Growth (Yr)

1.0K%

Rev. Growth (Qtr)

111.18%

TARS Earnings

Earnings (TTM)

-148.2M

Earnings Growth (Yr)

-52.57%

Earnings Growth (Qtr)

14.73%

Breaking Down TARS Revenue

Last 7 days

-7.5%

Last 30 days

-0.9%

Last 90 days

-21.9%

Trailing 12 Months

8.8%

How does TARS drawdown profile look like?

TARS Financial Health

Current Ratio

8.01

Debt/Equity

0.11

Debt/Cashflow

-4.45

TARS Investor Care

Shares Dilution (1Y)

40.96%

Diluted EPS (TTM)

-4.74

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	45.1M	0	0	0
2023	27.8M	0	14.4M	27.4M
2022	49.2M	41.4M	33.6M	25.8M
2021	0	0	0	57.0M

Get all data in R, Python etc through our Historical Stock Data APIs

About Tarsus Pharmaceuticals Inc

Tarsus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

CEO	Dr. Bobak R. Azamian M.D.
WEBSITE	tarsusrx.com
INDUSTRY	Biotechnology
EMPLOYEES	87

Tarsus Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Tarsus Pharmaceuticals Inc? What does TARS stand for in stocks?

TARS is the stock ticker symbol of Tarsus Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Tarsus Pharmaceuticals Inc (TARS)?

As of Fri Jul 26 2024, market cap of Tarsus Pharmaceuticals Inc is 945.3 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TARS stock?

You can check TARS's fair value in chart for subscribers.

Is Tarsus Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether TARS is over valued or under valued. Whether Tarsus Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Tarsus Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TARS.

What is Tarsus Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 26 2024, TARS's PE ratio (Price to Earnings) is -6.38 and Price to Sales (PS) ratio is 20.98. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TARS PE ratio will change depending on the future growth rate expectations of investors.